Clinical Trial: Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC) (China)

China, Oct. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134271

Registration Time: 2026/10/12

Type: Interventional study

Primary Sponsor: Shanghai Chest Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=343326

Published by HT Digital Content Services with permission from Health Daily Digest....